Headlines about OvaScience (NASDAQ:OVAS) have trended somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OvaScience earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.3361292594588 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

OvaScience (NASDAQ:OVAS) traded up 3.65% during midday trading on Friday, reaching $1.42. The company had a trading volume of 92,881 shares. The company’s 50 day moving average is $1.45 and its 200-day moving average is $1.48. The company’s market capitalization is $50.67 million. OvaScience has a 52-week low of $1.25 and a 52-week high of $7.92.

OvaScience (NASDAQ:OVAS) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.02. The firm had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.09 million. OvaScience had a negative net margin of 16,132.47% and a negative return on equity of 69.13%. The firm’s revenue for the quarter was down 55.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.62) earnings per share. Equities analysts expect that OvaScience will post ($1.67) earnings per share for the current fiscal year.

A number of equities analysts have commented on OVAS shares. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of OvaScience in a research report on Thursday, August 3rd. Zacks Investment Research upgraded shares of OvaScience from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect OvaScience (OVAS) Share Price” was originally published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.dailypolitical.com/2017/10/01/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-ovascience-ovas-share-price.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.